[Clinical evaluation of pirozadil, administered continuously over four and a half years, in patients with hyperlipoproteinemia type IIa].
With the goal to evaluate the long term efficacy and tolerance of pirozadil, 20 patients with hypercholesterolemia (type II a hyperlipoproteinemia) received this drug for 4.5 years. Lipidic parameters and the appearance of subjective manifestations related to the drug were periodically controlled. The triglyceride concentration (34%), total cholesterol (24%) and LDL-cholesterol (47%) decreased after 6 months of treatment with 1.5 to 2 g/day of pirozadil. These changes were more manifest during the second semester of therapy and did not show important oscolations in subsequent controls. Adverse effects, indicating the withdrawal of the drug were not encountered. Three patients had minor and transient epigastralgias. Taken as a whole, these results reinforce the usefulness of pirozadil in treating patients with hypercholesterolemias.
Cuchi de la Cuesta
C
C
Cuchi Alfaro
M T
MT
Cuchi Alfaro
C
C
D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage; D002784:Cholesterol / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000008:administration & dosage*
D000924:Anticholesteremic Agents; D011725:Pyridines; C015453:pirozadil; D002784:Cholesterol
Evaluación clínica del pirozadil administrado ininterrumpidamente durante 4.5 años a pacientes con hiperlipoproteinemia tipo IIa.